Company intelligence / Profile preview

Rejukon Biopharm

Ownership: Private
Development stage: Other

Overview

Rejukon Biopharm is conducting a Phase 1 clinical trial of RJK002, an intrathecal therapy targeting NEFL for amyotrophic lateral sclerosis. The company has additional preclinical programs in Alzheimer’s disease, dry age-related macular degeneration, and cardiovascular plaque deposition. Orphan drug designation was granted by the FDA for their ALS treatment candidate as of October 2023. Clinical results are not yet published beyond early safety/tolerability assessment.

Therapeutic areas: OphthalmologyNeurologyCardiovascular
Modalities: BiologicSmall molecule
Industry: Biotech

Partnerships

None publicly disclosed as of June, 2025.

Beyond the preview

Go deeper on Rejukon Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rejukon Biopharm.

Explore the full profile